The atopic dermatitis market, valued at USD 9.33 billion in 2024, is projected to grow at a CAGR of 15.10%, reaching USD 38.07 billion by 2034. Key drivers include increasing prevalence, FDA approvals ...

The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key ...

Calidi is joining an elite group of high-quality companies focused on making a difference in the world of cancer and genetic medicines, including Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Vertex ...

NetworkNewsWire Editorial Coverage NEW YORK, July 7, 2025 /CNW/ -- An estimated 20 million people are diagnosed annually with cancer, while cancer kills ...

Jim Parkinson, the designer behind Rolling Stone's iconic logo, has died at 83 after a long battle with Alzheimer’s, his friend confirmed.

The self-driving taxis feature a “Robotaxi” logo written out in a graffiti style on the car’s front doors. The scrawled typeface is reminiscent of the branding for the video game Cyberpunk ...

Is your iPhone stuck flashing the Apple logo? Learn what this issue means, why it happens, and how you can try to fix it.

Magic unveil new logo, uniforms for 2025-26 season Orlando has brought back a version of its classic logo and showed off 3 new uniform looks for next season.

After 16 years with the same primary logo and three main uniforms, the Magic are turning the page onto a new era that honors Orlando’s past. Fans of the franchise have waited for this rebrand… ...

With the team and Magic brand continuing to grow, the new logo fondly revisits the Magic’s history making an iconic and fan-favorite franchise symbol “the star” once again.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), along with its partner, Sanofi, said that they are reviewing the data and will discuss with regulatory authorities to evaluate next steps.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) faced a turbulent week as its shares plunged 17%, despite announcing encouraging results from a Phase 3 trial of itepekimab for chronic obstructive ...